Literature DB >> 22427345

Prevalence of cervical human papillomavirus (HPV) infection in Vanuatu.

Bernadette Aruhuri1, Len Tarivonda, Vanessa Tenet, Rohit Sinha, Peter J F Snijders, Gary Clifford, James Pang, Margaret McAdam, Chris J L M Meijer, Ian H Frazer, Silvia Franceschi.   

Abstract

To provide information on human papillomavirus (HPV) prevalence and the distribution of individual HPV types in Pacific Islands, we conducted a population-based survey in Vanuatu, South Pacific. Nine hundred and eighty-seven women between 18 and 64 years of age were included. GP5(+)/6(+)-mediated PCR assay was used for HPV testing. The prevalence of 44 HPV types was 28.4% corresponding to an age (world)-standardized prevalence of 25.0% [95% confidence interval (CI), 21.9%-28.0%]. The prevalence of high-risk (HR) HPV types was 21.7% (age-standardized prevalence of 19.2%; 95% CI, 16.4%-22.0%). Among 840 women with adequate cytologic results, 13.6% showed cervical abnormalities, including 3.6% with high-grade squamous intraepithelial lesions (HSIL) and 0.8% with invasive cervical carcinoma. HPV prevalence declined from 46.1% in women aged ≤21 to 15.3% in those ≥45 years. Being single was significantly associated with HPV positivity. HR HPV findings by PCR assay and hybrid capture 2 (HC2; conducted in Vanuatu) were moderately correlated (κ test = 0.59). The positive predictive values of HR HPV positivity for HSIL or worse were 27.6% for PCR and 35.2% for HC2 among women aged ≥30. Nearly half of screening-positive women could not be reevaluated mainly on account of the difficulty to trace back women. The availability of a rapid HPV testing method that allows see-and-treat approaches at the same visit would be, therefore, essential. On account of their high cumulative burden of cervical lesions, also women older than 40 years should be included in at least the first screening round in unscreened populations.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22427345     DOI: 10.1158/1940-6207.CAPR-11-0515

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  9 in total

1.  Human papillomavirus 45 genetic variation and cervical cancer risk worldwide.

Authors:  Alyce A Chen; Daniëlle A M Heideman; Debby Boon; Tarik Gheit; Peter J F Snijders; Massimo Tommasino; Silvia Franceschi; Gary M Clifford
Journal:  J Virol       Date:  2014-02-05       Impact factor: 5.103

2.  Mapping HPV Vaccination and Cervical Cancer Screening Practice in the Pacific Region-Strengthening National and Regional Cervical Cancer Prevention.

Authors:  J Obel; J McKenzie; L E Buenconsejo-Lum; A M Durand; A Ekeroma; Y Souares; D Hoy; W Baravilala; S M Garland; S K Kjaer; A Roth
Journal:  Asian Pac J Cancer Prev       Date:  2015

3.  Human Papillomavirus 18 Genetic Variation and Cervical Cancer Risk Worldwide.

Authors:  Alyce A Chen; Tarik Gheit; Silvia Franceschi; Massimo Tommasino; Gary M Clifford
Journal:  J Virol       Date:  2015-08-12       Impact factor: 5.103

4.  Human papillomavirus 33 worldwide genetic variation and associated risk of cervical cancer.

Authors:  Alyce A Chen; Daniëlle A M Heideman; Debby Boon; Zigui Chen; Robert D Burk; Hugo De Vuyst; Tarik Gheit; Peter J F Snijders; Massimo Tommasino; Silvia Franceschi; Gary M Clifford
Journal:  Virology       Date:  2013-11-12       Impact factor: 3.616

5.  Human papillomavirus infection in Bhutan at the moment of implementation of a national HPV vaccination programme.

Authors:  Ugyen Tshomo; Silvia Franceschi; Dorji Dorji; Iacopo Baussano; Vanessa Tenet; Peter J F Snijders; Chris J L M Meijer; Maaike C G Bleeker; Tarik Gheit; Massimo Tommasino; Gary M Clifford
Journal:  BMC Infect Dis       Date:  2014-07-22       Impact factor: 3.090

6.  Assessment of a new low-cost, PCR-based strategy for high-risk human papillomavirus DNA detection for cervical cancer prevention.

Authors:  Pedro Surriabre; Andrea Torrico; Tania Vargas; Fuantina Ugarte; Patricia Rodriguez; Véronique Fontaine
Journal:  BMC Infect Dis       Date:  2019-10-15       Impact factor: 3.090

7.  Type distribution of human papillomavirus among adult women diagnosed with invasive cervical cancer (stage 1b or higher) in New Zealand.

Authors:  Peter Sykes; Kusuma Gopala; Ai Ling Tan; Diane Kenwright; Simone Petrich; Anco Molijn; Jing Chen
Journal:  BMC Infect Dis       Date:  2014-07-08       Impact factor: 3.090

8.  Prevalence of HPV infection and other risk factors in a Fijian population.

Authors:  Sunia Foliaki; Naomi Brewer; Neil Pearce; Peter Jf Snijders; Chris Jlm Meijer; Lepani Waqatakirewa; Gary M Clifford; Silvia Franceschi
Journal:  Infect Agent Cancer       Date:  2014-04-28       Impact factor: 2.965

9.  Human papillomavirus infection in Rwanda at the moment of implementation of a national HPV vaccination programme.

Authors:  Fidele Ngabo; Silvia Franceschi; Iacopo Baussano; M Chantal Umulisa; Peter J F Snijders; Anne M Uyterlinde; Fulvio Lazzarato; Vanessa Tenet; Maurice Gatera; Agnes Binagwaho; Gary M Clifford
Journal:  BMC Infect Dis       Date:  2016-05-24       Impact factor: 3.090

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.